Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Elite Pharmaceuticals Inc. (ELTP) had Revenue of $36.32M for the most recently reported fiscal quarter, ending 2025-09-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-09-30

Income Statement Financials
Revenue	$36.32M
Net Income	$13.70M
Cost of Goods Sold	$22.25M
Gross Profit	$14.07M
Operating Expenses	$28.11M
Operating Income	$8.21M
Non-Operating Income/Expense	$7.48M
Pre-Tax Income	$15.69M
Normalized Pre-Tax Income	$15.69M
Income after Taxes	$13.70M
Income from Continuous Operations	$13.70M
Consolidated Net Income/Loss	$13.70M
Normalized Income after Taxes	$13.70M
EBIT	$8.21M
EBITDA	$8.73M
Weighted-Average Shares Outstanding (Basic)	1.07B
Weighted-Average Shares Outstanding (Diluted)	1.14B
Earnings per Share (EPS) (Basic)	$0.01
Earnings per Share (EPS) (Diluted)	$0.01
Balance Sheet Financials
Current Assets	$85.79M
Property, Plant, and Equipment	$10.10M
Long-Term Assets	$31.45M
Total Assets	$117.25M
Current Liabilities	$10.67M
Long-Term Debt	$3.91M
Long-Term Liabilities	$44.99M
Total Liabilities	$55.66M
Common Equity	$61.59M
Tangible Shareholders Equity	$55.95M
Shareholders Equity	$61.59M
Common Shares Outstanding	1.07B
Cash Flow Statement Financials
Cash Flow from Operating Activities	$19.88M
Cash Flow from Investing Activities	$-0.32M
Cash Flow from Financial Activities	$-4.25M
Beginning Cash	$11.77M
End Cash	$27.08M
Increase/Decrease in Cash	$15.31M
Stock-Based Compensation	$0.10M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	8.04
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.06
Debt to Equity Ratio	0.07
Gross Margin	38.75%
Operating Margin	22.61%
EBIT Margin	22.61%
EBITDA Margin	--
Pre-Tax Profit Margin	43.20%
Profit Margin	37.73%
Free Cash Flow	$19.56M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.31
Inventory Turnover	1.22
Receiveable Turnover	0.89
Days Sales in Receivables	101.27
Return on Equity	22.25%
Return on Tangible Equity	24.49%
Return on Assets	11.69%
Return on Investments	20.92%
Book Value Per Share	$0.06
Free Cash Flow per Share	$0.02
Operating Cash Flow per Share	$0.02

Data from Zacks Investment Research, Inc.